Afuco™ Anti-APP ADCC Therapeutic Antibody (Crenezumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Abeta. Crenezumab is a humanized monoclonal antibody against human 1-40 and 1-42 Beta amyloid, which is being investigated as a treatment of Alzheimer's disease.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-226 |
| Pricing | Inquiry |
| Host | Human |
| Target | APP |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IF, IP, Neut, FuncS, ELISA |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |